Design, synthesis and biological evaluation of erythrina derivatives bearing a 1,2,3-triazole moiety as PARP-1 inhibitors
作者:Shuai Li、Xin-yang Li、Ting-jian Zhang、Ju Zhu、Wen-han Xue、Xin-hua Qian、Fan-hao Meng
DOI:10.1016/j.bioorg.2020.103575
日期:2020.3
(PARP-1) have shown to be promising in clinical trials against cancer, and many researchers are interested in the development of new PARP-1 inhibitors. Herein, we designed and synthesized 44 novel erythrina derivatives bearing a 1,2,3-triazole moiety as PARP-1 inhibitors. MTT assay results indicated that compound 10b had the most potent anti-proliferative activity against A549 cells among five cancer
聚(ADP-核糖)聚合酶-1(PARP-1)的抑制剂在抗癌的临床试验中已显示出前景广阔,许多研究人员对新型PARP-1抑制剂的开发感兴趣。在这里,我们设计和合成了44个带有1,2,3-三唑部分的新型赤藓类衍生物作为PARP-1抑制剂。MTT测定结果表明,化合物5b在五个癌细胞中对A549细胞具有最有效的抗增殖活性。化合物10b的体外酶抑制活性也明显优于rucaparib。此外,化合物10b对肺癌细胞的选择性指数高于rucaparib。流式细胞仪分析表明,化合物10b通过线粒体途径诱导A549细胞凋亡。Western印迹分析表明,化合物10b能够有效抑制PAR的生物合成,并且比rucaparib更有效。同样,化合物10b能够上调bax / bcl-2的比例,激活caspase-3,并最终诱导A549细胞凋亡。综合结果表明,新型基于非酰胺的PARP-1抑制剂的发现具有重要的研究意义,并为药物的未来发展提供了更好的选择。